Back to Market返回行情

NEPH Nephros, Inc.

USHealthcare
$4.32-6.59%ClosedMarket Cap: $46.9M

As of 2026-08-17

Why NEPH matters now

Nephros, Inc. (NEPH) is a US stock in Healthcare. The latest InvestLog snapshot shows $4.32 with -6.59% on the session and $46.9M in market capitalization; recent performance reads 1-month -13.22% and YTD -35.45%.

The latest financial table shown here is Q1 2026, with revenue of $5.2M, net income of $140.0K, and EPS of $0.01. Investors can compare that operating picture with valuation signals such as P/E 24.78 and FCF yield -1.0%.

The latest indexable market news headline is "Nephros Q2 Earnings Call Highlights" from Defense World.

Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes Amron Arthur H filing A-Award. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

24.78

PEG

0.02

P/B

3.14

P/S

1.79

EV/EBITDA

36.35

DCF Value

$-6.00

FCF Yield

-1.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

59.1%

Operating Margin

3.5%

Net Margin

4.1%

ROE

7.7%

ROA

5.6%

ROIC

5.7%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$5.2M$140.0K$0.01
Q4 2025$4.7M$62.0K$0.01
FY 2025$18.8M$1.2M$0.11
Q3 2025$4.8M$337.0K$0.03

Analyst Ratings

Consensus

Buy

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

Strong Buy: 2Buy: 0Hold: 0Sell: 0Strong Sell: 0
Maxim GroupBuy
2025-08-08

Trading Activity

Insider Trades

Amron Arthur Hdirector
Sell2026-06-12
Krandel Judyofficer: Chief Financial Officer
Sell2026-03-25
Banks Robert R. Jr.officer: President and CEO
Sell2026-03-25
Krandel Judyofficer: Chief Financial Officer
Sell2026-03-25
Banks Robert R. Jr.officer: President and CEO
Sell2026-03-25

Company Info

Sector

Healthcare

Industry

Medical - Instruments & Supplies

Country

US

Exchange

Beta

1.50

Nephros, Inc. is a company that specializes in developing and marketing sophisticated water purification solutions across the United States, catering to both the medical and commercial sectors. Its operations are structured into three primary segments: Water Filtration, Pathogen Detection, and Renal Products. Within its Water Filtration division, Nephros offers advanced ultrafiltration products. These are vital in dialysis centers for eradicating biological contaminants from water and bicarbonate concentrate, and are also deployed in hospitals to prevent infections from waterborne pathogens such as Legionella and Pseudomonas. Their utility extends to military installations, outdoor recreation, commercial establishments, and various other healthcare facilities. The Pathogen Detection segment focuses on developing and distributing real-time water testing systems, which deliver critical, actionable data regarding waterborne pathogens. Furthermore, under its Renal Products segment, the company provides medical devices designed for individuals suffering from renal disease, notably including a second-generation hemodiafiltration system tailored for patients with end-stage renal disease. Additionally, Nephros markets a range of water filters under the Nephros and AETHER brands. These filters are engineered not only to enhance water taste and eliminate odors but also to significantly reduce biofilm, bacteria, and scale accumulation in downstream equipment, serving the food service, hospitality, convenience store, and healthcare industries. Established in 1997, Nephros, Inc. maintains its corporate headquarters in South Orange, New Jersey.